Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Associated Therapies
-
Clinical Trials
Related News

Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Clopidogrel
First Posted Date
2006-12-20
Last Posted Date
2011-05-05
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
140
Registration Number
NCT00413608
Locations
🇫🇷

Hôpital Européen Georges Pompidou, Paris, France

Retinal Blood Flow and Microthrombi in Type 1 Diabetes

Phase 2
Completed
Conditions
Diabetic Retinopathy
Diabetes
First Posted Date
2006-12-04
Last Posted Date
2015-10-30
Lead Sponsor
Schepens Eye Research Institute
Target Recruit Count
100
Registration Number
NCT00406991
Locations
🇺🇸

Schepens Eye Research Institute, Boston, Massachusetts, United States

Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation

Phase 4
Completed
Conditions
Acute Coronary Syndrome
First Posted Date
2006-11-27
Last Posted Date
2006-11-29
Lead Sponsor
Shenyang Northern Hospital
Registration Number
NCT00404053

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Phase 3
Completed
Conditions
Acute Coronary Syndrome
Interventions
Drug: Clopidogrel
Drug: Ticagrelor
First Posted Date
2006-10-25
Last Posted Date
2012-03-13
Lead Sponsor
AstraZeneca
Target Recruit Count
18624
Registration Number
NCT00391872
Locations
🇬🇧

Research Site, Swansea, United Kingdom

The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)

Phase 2
Completed
Conditions
Acute Coronary Syndrome
Interventions
Drug: Prasugrel
Drug: Clopidogrel
First Posted Date
2006-10-11
Last Posted Date
2010-09-16
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
56
Registration Number
NCT00385944
Locations
🇫🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

First Posted Date
2006-10-06
Last Posted Date
2014-05-05
Lead Sponsor
The Medicines Company
Target Recruit Count
5364
Registration Number
NCT00385138
Locations
🇺🇸

Innovis Health, Fargo, North Dakota, United States

ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"

Phase 2
Completed
Conditions
Ischemia
First Posted Date
2006-08-04
Last Posted Date
2010-08-31
Lead Sponsor
Sanofi
Target Recruit Count
110
Registration Number
NCT00360386

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

First Posted Date
2006-07-28
Last Posted Date
2010-08-31
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
201
Registration Number
NCT00357968
Locations
🇮🇱

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

First Posted Date
2006-07-25
Last Posted Date
2010-11-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
139
Registration Number
NCT00356135
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

Phase 4
Completed
Conditions
Coronary Artery Disease
First Posted Date
2006-06-23
Last Posted Date
2008-08-21
Lead Sponsor
Intermountain Health Care, Inc.
Target Recruit Count
100
Registration Number
NCT00343876
Locations
🇺🇸

LDS Hospital, Salt Lake City, Utah, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy